ArticleFrontiers in public health2022

Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.

Qiong Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.